<DOC>
	<DOCNO>NCT00709579</DOCNO>
	<brief_summary>Methodology : Phase III study , single centre , double blind , versus excipient , randomise , controlateral design . Selection patient : Number subject require 60 : - 30 patient need oral corticotherapy - 30 patient need topical corticotherapy</brief_summary>
	<brief_title>Physiopathological Study Pharmacological Modulation Cutaneous Atrophy 's Markers Induced Glucocorticoids</brief_title>
	<detailed_description>Study conduct Two step patient : 1. first step last 3 month : assessment change mechanisms involve ACIC RV3391A cream ( M0 à M3 ) . At begin corticotherapy , patient apply RV3391A anterior side forearm placebo side ( randomise ) 3 month . Clinical exam objective measurement realise . This step allow u describe compare evolution cutaneous atrophy 's marker produce glucocorticoïds marker M0 M3 : - topical oral corticotherapy - RV3391A placebo . 2. second step , cohort follow-up , lead end first step ( M3 à M24 ) The period second step depend progression patient 's disease period medical follow-up . This period may last 24th month inclusion study . The patient apply RV3391A placebo anymore . They followed-up CHU.Assessments cutaneous atrophy 's marker produce glucocorticoïds realise M6 , M12 , M18 M24 non invasive method ( clinical scoring , imaging , extensometry ) exactly describe long-term period evolution ACIC . The assessment forearm receive placebo allow u know natural history skin atrophy induce corticotherapy .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Patients need oral corticotherapy : age 50 year first corticotherapy 0.5 mg/kg/day expectable period corticotherapy 10 mg/day 3 month sign write informed consent form register social security health insurance system Patients need topical corticotherapy : age 50 year topical corticotherapy high high potency corticoid 10 g/day expectable period topical corticotherapy 3 month sign write informed consent form register social security health insurance system Oral topical corticotherapy within last 3 month Cutaneous inflammation anterior side forearm Medical history psychosis induce corticotherapy Medical history allergy RV3391A product excipients . Medical history allergy mineral cream Avene SPF50 excipients . Medical history allergy latex , surgical tape , chlorhexidine , lidocaine xylocaine Clotting disorder anticoagulant intake Healing disorder Women postmenopausal woman Substitutive estrogenotherapy le 6 month Impossibility register Volunteers National Register Inability comply requirement clinical monitoring program , Inability personally sign informed consent form Is deprive freedom administrative judicial decision ; guardianship protective custody</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Patients need oral corticotherapy</keyword>
	<keyword>Patients need topical corticotherapy</keyword>
	<keyword>Corticotherapy</keyword>
</DOC>